Placebo (Lisaftoclax), Lisaftoclax, Azacitidine Seacross 25 mg/mL powder for suspension for injection
APG2575MG301
Phase 3 small_molecule active
Quick answer
Placebo (Lisaftoclax), Lisaftoclax, Azacitidine Seacross 25 mg/mL powder for suspension for injection for Newly Diagnosed Higher Risk Myelodysplastic Syndrome is a Phase 3 program (small_molecule) at Pharma Mar S.A. with 1 ClinicalTrials.gov record(s).
Program details
- Company
- Pharma Mar S.A.
- Indication
- Newly Diagnosed Higher Risk Myelodysplastic Syndrome
- Phase
- Phase 3
- Modality
- small_molecule
- Status
- active